Camrelizumab combined with FOLFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma.
Ying Liu(Peking University), Danyang Li(Henan University of Technology), Jie Ma(Zhengzhou University), Qingxin Xia(Zhengzhou University), Chengjuan Zhang(Zhengzhou University), Baodong Li(Zhengzhou University), Hongle Li(Shanghai Jiao Tong University), Jinbang Wang(Dalian National Laboratory for Clean Energy), Guangsen Han(Zhengzhou University), Jing Zhuang(Zhengzhou University), Yuzhou Zhao(Capital Medical University), Ke Li(Zhengzhou University), Lei Qiao(State Key Laboratory for Innovation and Transformation of Luobing Theory), Juan Yu(Southern Medical University), Zhimeng Li(Zhengzhou University), Shuning Xu(Zhengzhou University), Gangcheng Wang(Zhengzhou University), Gaizhen Kuang(Zhengzhou University)
Cited by 18
Related Papers
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
IL-2 regulates tumor-reactive CD8+ T cell exhaustion by activating the aryl hydrocarbon receptor
|Nature Immunology|2021|374
Tumor-associated neutrophils induce EMT by IL-17a to promote migration and invasion in gastric cancer cells
|Journal of Experimental & Clinical Cancer Research|2019|324
MEK inhibitors for the treatment of non-small cell lung cancer
|Journal of Hematology & Oncology|2021|300
Direct Observation of Cyclic Carbenium Ions and Their Role in the Catalytic Cycle of the Methanol‐to‐Olefin Reaction over Chabazite Zeolites
|Angewandte Chemie International Edition|2013|238